RNXT

RenovoRx Inc

Add to Watchlist

Advanced Chart

1.270

-0.03(-2.308%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.300

Open

1.300

VWAP

1.28

Vol

51.37K

Mkt Cap

46.45M

Low

1.270

Amount

65.65K

EV/EBITDA(TTM)

Total Shares

23.95M

31.86M

EV/OCF(TTM)

P/S(TTM)

RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

4 Analyst Rating

333.07% Upside

Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 11.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

333.07% Upside

Current: 1.270

Low

3.00

Averages

5.50

High

11.50

333.07% Upside

Current: 1.270

Low

3.00

Averages

5.50

High

11.50

Ascendiant

Edward Woo

Buy

maintain

$11

2025-06-05

Reason

Ascendiant

Edward Woo

Price Target

$11

2025-06-05

maintain

Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-04-04

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-04-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Initiates

2025-03-27

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-27

Initiates

Strong Buy

Reason

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$8.25 → $9

2024-12-10

Reason

Ascendiant Capital

Edward Woo

Price Target

$8.25 → $9

2024-12-10

Maintains

Strong Buy

Reason

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$8 → $8.25

2024-09-12

Reason

Ascendiant Capital

Edward Woo

Price Target

$8 → $8.25

2024-09-12

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for RenovoRx Inc (RNXT.O) is -3.60, compared to its 5-year average forward P/E of -3.02. For a more detailed relative valuation and DCF analysis to assess RenovoRx Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.02

Current PE

-3.60

Overvalued PE

-1.30

Undervalued PE

-4.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.22

Current PS

31.09

Overvalued PS

9.93

Undervalued PS

-5.49